자료실


Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen" by Tong et al.

After reading the article, see the complementary Gastroenterology article.

Abstract:
Background & Aims
During the natural course of chronic hepatitis B virus infection, a small proportion of patients experience hepatitis B surface antigen (HBsAg) seroclearance. However, the long-term clinical outcomes of this process are not well established.

Methods
Thirty-five patients with chronic hepatitis B, followed between 1976 and 2008 at a community liver clinic, experienced HBsAg seroclearance. Ten patients were Caucasian and 25 were Asian. These patients continued to undergo surveillance for hepatocellular carcinoma that included test for α-fetoprotein levels and abdominal ultrasound examinations. The median follow-up time was 185 months (range, 27–400 months).

Results
During the initial visit to the clinic, the median age of the patients was 41 years (range, 1.5–72 years). Eighteen patients (51.4%) were hepatitis B e antigen (HBeAg) positive 25 (71.4%) were hepatitis B virus DNA positive, and 13 (37.1%) had cirrhosis. At the time of HBsAg loss, the median age was 54 years (range, 13–77 years) and all were hepatitis B e antigen- as well as hepatitis B virus DNA negative. During the long-term follow-up, 4 patients with cirrhosis developed hepatocellular carcinoma (HCC), which was discovered by ultrasound examination. Factors associated with development of HCC were low baseline levels of albumin (P = .04), family histories of HBsAg positivity (P = .01) and HCC (P = .04), and age of less than 50 years at the time of HBsAg clearance (P = .03).

Conclusions
HCC can still develop after HBsAg seroclearance. Thus, surveillance should be continued after HBsAg loss in the same manner as for HBsAg positive patients.

Read the Article :  http://www.cghjournal.org/article/PIIS1542356509003723/abstract

Tong MJ, Nguyen MO, Tong LT, et al. Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2009;7:889-893.

Copyright 2009 AGA Institute
(A) Patient A: a 55-year-old Asian male. (B) Patient B: a 67-year-old Asian male. (C) Patient C: a 69-year-old Caucasian male. (D) Patient D: a 73-year-old Asian male. AFP, alphafetoprotein; ALT, alanine aminotransferase.

Tong MJ, Nguyen MO, Tong LT, et al. Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2009;7:889-893.

Copyright 2009 AGA Institute
번호 제목 글쓴이 날짜 조회 수
273 김창섭 선생님 강의(질문과 답)-"B형간염과 간질환" 2008년4월. (2) [1] 윤구현 2009.01.09 4339
272 B형간염 환자의 채용 및 고용관리 지침 [1] file 한상율 2003.06.04 4044
271 B형간염바이러스감염때 어떤이는 회복되고 어떤이는 그렇지 않나? [6] 양전호 2006.06.12 3975
» 간암에 대한 최근 흥미로운 저널내용입니다. [5] 양전호 2009.08.22 3954
269 HBV DNA검사의 보험급여기준(2015-12-15) [1] file 윤구현 2008.07.28 3901
268 만성C형 간염치료제 하보니의 효과와 안전성 (광주 한정렬내과) 南道光州한정렬 2019.09.09 3710
267 국가인권위원회 - 채용신체검사 개선방안 마련을 위한 청문회 자료집 [1] file 윤구현 2004.01.04 3465
266 간추린 간질환 길잡이 - 대한간학회, 간염퇴치를 위한 의사들의 모임 [2] 윤구현 2003.01.24 3399
265 만성 간염 진료에서 의료보험 문제 [5] 한상율 2005.05.16 3344
264 만성B형간염치료제들의 가격인하와 보험급여기준 변경 [2] file 윤구현 2009.01.27 3341
263 흡연이 간질환에 미치는 영향 [4] 윤구현 2007.07.12 3287
262 HBV DNA copy수와 간암발생과의 관계 [1] file 양전호 2006.04.08 3200
261 공무원채용신체검사업무처리요람(개정전) [3] file 한상율 2003.02.13 3183
260 2009년 9월 1일 시행. 헵세라와 바라크루드1mg의 보험급여 변경 내용 [1] file 윤구현 2009.08.31 3169
259 간염퇴치를 위한 의사들의 모임의 건강정보 - 간질환 시리즈 [1] 윤구현 2003.01.24 3157
258 행정자치부의 공무원채용신체검사시 B형간염바이러스 보유자에 대한 판정기준 [1] file 한상율 2003.06.04 3100
257 수직감염(모유수유)에 대해 [5] 윤구현 2008.12.03 3066
256 2009년 유럽간학회 만성B형간염 관리 가이드라인 [1] file 윤구현 2009.09.12 2977
255 엔테카비어의 5년 치료 성적이 나왔군요 보세요 [5] 양전호 2010.01.11 2975
254 신약개발이야기4) 가난한 이들에겐 아플 자유밖에 없는가? -프레시안 이은희 2003-03-11 [1] 윤구현 2003.04.11 2959